About MoST-LLy Study
The Molecular Screening and Therapeutics in leukemia and lymphoma (MoST-LLy) study is a national clinical initiative aimed at improving treatment outcomes for patients with blood cancers. MoST-LLy uses genetic testing to identify personalised treatment options for patients with leukaemia, lymphoma, and other blood cancers.
The MoST-LLy study is a haematology extension of the MoST program.
Process:
1. Referral from Haematologist
2. Extraction of blood cancer DNA
3. Genetic sequencing and analysis
4. Discuss results with Haematologist
5. Follow up to review any treatment referrals
If a patient is suitable for the MoST-LLy study, and consents to participate, their blood cancer is tested to see if their DNA contains genetic biomarkers that may guide treatment. This process is called molecular screening or comprehensive genetic panel (CPG) testing. After a patient’s blood cancer is tested, a report is sent to the referring haematologist including:
(i) Any genetic biomarkers that were identified in the blood cancer, and
(ii) Any types of treatment that may be suitable (if found).
Who is suitable for the MoST-LLy Program?
Blood cancer patients 18 years and over, with advanced blood cancer of any type.
How can a patient enrol in the MoST-LLy Program?
A patient is asked to discuss the MoST-LLy study with their treating Haematologist.
Haematologist’s can review eligibility criteria and refer potentially eligible patient’s through a secure online MoST-LLy referral form with the patients medical history and a Pathology Report (to confirm the type of blood cancer and assist the study team to request a sample for testing).
If you are interested in the MoST-LLy study and would like a copy of the eligibility criteria or the MoST-LLy Referral form, please contact the Clinical Trial Project Managers, listed below.
The ethical aspects of this study have been approved by the HREC of Metro South Health EC00167 (HREC/2024/QMS/113451).
This study is made possible through the support of the Leukaemia Foundation of Australia, Tour de Cure and an MRFF Grant with CIA Prof Steven Lane.
Participation
- patients with advanced blood cancer of any type
- patients aged 18 years and over
Participate in the Trial
Contact
Chief Investigator: Prof Steven Lane (Clinical Lead)
Clinical Trials Project Managers: Gerlinda Amor and Helen Christensen
For more information about this study, contact us:
- T: 07 3845 3678 or 0487 400 607
- E: mostlly@qimrb.edu.au
Haematologist's referral link:
https://redcap.qimrberghofer.edu.au/surveys/?s=JKJ3N9NCFJ9FHDTW